EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity

Alvaro Lopez-Sanchez iD, Henri Chédotal iD, Ram Pravin Kumar Muthuramalingam iD, Marine Thomas, Jia Ning Nicolette Yau iD, Priya Ranjan Sahoo iD, Clotilde Policar iD, Frédéric Batteux iD, Kadda Medjoubi iD, Andrea Somogyi iD, Giulia Adriani iD, Carole Nicco iD und 3 weitere

Advanced Healthcare Materials · 2025-09 · 14 (24)

DOI: 10.1002/adhm.202501847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 06.07.2025. Verfasst von Alvaro Lopez-Sanchez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire Chimie Physique et Chimie du Vivant CPCV, Département de chimie, Ecole normale supérieure, PSL University, Sorbonne Université, CNRS, 24 …. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Manganese, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sorbonne Université and Ecole Doctorale de Chimie Moléculaire Paris Centre, Fondation de la Maison de la Chimie, Agence Nationale de la Recherche (ANR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As FDA‐approved platinum (Pt) anticancer drugs (e.g. cisplatin, oxaliplatin and carboplatin) grapple with clinical challenges including chemoresistance and systemic side‐effects, Pt(IV) prodrugs have emerged as potent alternative chemotherapies. In this work, a novel bimetallic dual‐action Pt(IV) prodrug bearing a manganese (Mn) superoxide dismutase mimic (SODm) is presented, demonstrating high stability in solution. The prodrug displays intrinsic antisuperoxide properties and in vitro comparable cytotoxic activities to that of oxaliplatin in 2‐ and 3D colorectal cancer cellular models, as well as an increase in intracellular reactive oxygen species (ROS) production. The prodrug is further evaluated in an in vivo mice model for colorectal cancer, demonstrating a similar performance to that of oxaliplatin. Additionally, a total tumor remission is reached with a PEGylated micellar encapsulation of the prodrug. This novel formulation increases the lifetime of the prodrug and therefore its tumoral uptake and plasma content with respect to the unencapsulated drug. This enhanced activity suggests the therapeutic potential of said formulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsAntineoplastic AgentsManganeseColorectal NeoplasmsPlatinumOrganoplatinum CompoundsAnimalsHumansMiceOxidation-ReductionCell Line, TumorReactive Oxygen SpeciesOxaliplatin

Stichwörter der Autor:innen

SOD mimicsdrug discoverynanoformulationoxaliplatinoxidative stressplatinum prodrugs

Substanzen

ProdrugsAntineoplastic AgentsManganeseReactive Oxygen SpeciesOxaliplatinPlatinumOrganoplatinum Compounds

Autor:innen und Institutionen

  • Laboratoire Chimie Physique et Chimie du Vivant CPCV, Département de chimie, Ecole normale supérieure, PSL University, Sorbonne Université, CNRS, 24 rue Lhomond, Paris, 75005, France.
  • Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, 4 Science Drive 2, Singapore, 117544, Singapore.
  • Institut Cochin, INSERM U1016 CNRS UMR 8104, Université Paris Cité, 22 rue Méchain, Paris, 75014, France.
  • Synchrotron SOLEIL, BP 48, Saint Aubin, Gif sur Yvette, 91192, France.
  • Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos, 138648, Singapore.
  • Department of Biomedical Engineering, National University of Singapore, 4 Engineering Drive 3, Singapore, 117583, Singapore.

ORCID-Profile: Alvaro Lopez-Sanchez, Henri Chédotal, Ram Pravin Kumar Muthuramalingam, Jia Ning Nicolette Yau, Priya Ranjan Sahoo, Clotilde Policar, Frédéric Batteux, Kadda Medjoubi, Andrea Somogyi, Giulia Adriani, Carole Nicco, Romain Coriat, Giorgia Pastorin, Hélène C Bertrand

Förderung

  • Sorbonne Université and Ecole Doctorale de Chimie Moléculaire Paris Centre
  • Fondation de la Maison de la Chimie
  • Agence Nationale de la Recherche (ANR)
  • Sorbonne Université Emergence
  • Ligue contre le Cancer
  • CNRS International Emerging Action
  • Merlion Project
  • Singapore Immunology Network, Agency for Science Technology and Research (A*STAR)

Zitieren

APA

Lopez-Sanchez, A., Chédotal, H., Muthuramalingam, R. P. K., Thomas, M., Yau, J. N. N., Sahoo, P. R., Policar, C., Batteux, F., Medjoubi, K., Somogyi, A., Adriani, G., Nicco, C., Coriat, R., Pastorin, G., & Bertrand, H. C. (2025). A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity. Advanced Healthcare Materials, 14(24). https://doi.org/10.1002/adhm.202501847

Vancouver

Lopez-Sanchez A, Chédotal H, Muthuramalingam RPK, Thomas M, Yau JNN, Sahoo PR, et al. A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity. Advanced Healthcare Materials. 2025;14(24). doi:10.1002/adhm.202501847

BibTeX
@article{LopezSanchez2025,
  author = {Lopez-Sanchez, Alvaro and Chédotal, Henri and Muthuramalingam, Ram Pravin Kumar and Thomas, Marine and Yau, Jia Ning Nicolette and Sahoo, Priya Ranjan and Policar, Clotilde and Batteux, Frédéric and Medjoubi, Kadda and Somogyi, Andrea and Adriani, Giulia and Nicco, Carole and Coriat, Romain and Pastorin, Giorgia and Bertrand, Hélène C},
  title = {A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  volume = {14},
  number = {24},
  doi = {10.1002/adhm.202501847}
}
Kostenlos starten →